|
|
Vaccine Detail
|
Oral Cancer Vaccine V3-OVA |
| Vaccine Information |
- Vaccine Name: Oral Cancer Vaccine V3-OVA
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: ovarian cancer antigens (NCIT_C159540; NCT03556566)
- Immunization Route: oral pill
- Description: This is an oral vaccine composed of autologous ovarian cancer antigens obtained from hydrolyzed, inactivated blood and tumor tissue of patients with ovarian cancer, with potential immunostimulatory and antineoplastic activities. The ovarian cancer antigens stimulate the immune system and activate a cytotoxic T-lymphocyte (CTL) immune response against ovarian cancer cells. (NCIT_C159540) Ovarian cancer patients can be given one pill a day for three months. (NCT03556566)
|
| Host Response |
|
|
| References |
NCIT_C159540: Oral Cancer Vaccine V3-OVA [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C159540]
NCT03556566: Open Label Immunotherapy Trial for Ovarian Cancer (V3-OVA) [https://clinicaltrials.gov/study/NCT03556566]
|
|
